SCHEDULE: Vanguard Group Adjusts Day One Biopharma Ownership Reporting

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Day One Biopharmaceuticals Inc. following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 1 to its Schedule 13G for Day One Biopharmaceuticals Inc.
• The filing reports 0% beneficial ownership of Day One Biopharmaceuticals Inc. common stock by The Vanguard Group.
• This change is a result of an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain Vanguard subsidiaries or business divisions will now report their beneficial ownership separately (on a disaggregated basis).
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over the securities now reported by these disaggregated entities.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral compliance filing. It reflects an internal administrative change at Vanguard and does not convey positive or negative sentiment regarding Day One Biopharmaceuticals Inc.'s operational or financial performance.

Positives

• The filing indicates compliance with SEC reporting requirements following an internal corporate restructuring at The Vanguard Group.
• The internal realignment allows for more granular reporting of beneficial ownership by Vanguard's subsidiaries.

Negatives

• No direct negatives for Day One Biopharmaceuticals Inc. are indicated in this compliance filing.

Risks

• No specific risks related to Day One Biopharmaceuticals Inc. are mentioned in this filing. The filing is a compliance update from Vanguard.

Industry Context

StockSavvy.ai notes that large institutional investors like The Vanguard Group frequently undergo internal restructurings or realignments that necessitate updates to their beneficial ownership filings. This disaggregation of reporting is a common practice to ensure compliance with SEC regulations and reflect changes in internal fund management structures, rather than a change in investment strategy for the underlying securities.

Stakeholder Impact

• Shareholders of Day One Biopharmaceuticals Inc.: Minimal direct impact, as the change reflects Vanguard's internal reporting structure rather than a divestment or change in investment strategy. The overall institutional ownership by Vanguard entities may remain similar, just reported differently.
• The Vanguard Group: Ensures compliance with SEC regulations following an internal realignment, potentially leading to more transparent reporting by its various subsidiaries.

Key Dates

Recommendation

This Schedule 13G/A filing from The Vanguard Group is a purely administrative update reflecting an internal corporate realignment and a change in how Vanguard's beneficial ownership is reported. It does not provide any new information regarding Day One Biopharmaceuticals Inc.'s operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as the filing itself offers no fundamental reason to alter an existing position.

Keywords

Vanguard Group, Day One Biopharmaceuticals, Schedule 13G, Beneficial Ownership, SEC Filing, Institutional Investor, Common Stock, Investment Adviser, Corporate Realignment